Identification of pharmacoresistant epilepsy
- PMID: 19853220
- PMCID: PMC2827183
- DOI: 10.1016/j.ncl.2009.06.001
Identification of pharmacoresistant epilepsy
Abstract
There is no single definition of pharmacoresistant (intractable, refractory) epilepsy. Prospective identification of pharmacoresistance is complicated by the variability of its appearance across different types of epilepsy and the variability of seizure control within a given patient over time. Failure of informative trials of two appropriate antiepileptic drugs has been recommended as a threshold that should trigger referral for evaluation at a comprehensive epilepsy center. Maximizing seizure control is imperative for reducing the risks and consequences of epilepsy, including the cognitive and psychiatric comorbidities and even sudden death.
References
-
- Arts WFM, Brouwer OF, Peters ACB, et al. Course and prognosis of childhood epilepsy: 5-year follow-up of the Dutch study of epilepsy in childhood. Brain. 2004;127:1774. - PubMed
-
- Arzimanoglou A, Ryvlin P. Toward a clinically meaningful definition of drug resistance. In: Kahane P, Berg A, Loscher W, et al., editors. Drug Resistant Epilepsy. Montrouge: John Libbey Eurotext; 2008. p. 1.
-
- Bell GS, Gaitatzis A, Bell CL, et al. Drowning in people with epilepsy: How great is the risk? Neurology. 2008;71:578. - PubMed
-
- Berg AT. Introduction to the epilepsies. In: Engel JPT, editor. Epilepsy: A Comprehensive Text. 2. Philadelphia: Lippincott-Raven Press; 2008. p. 761.
-
- Berg AT. The risks, correlates, and temporal patterns of intractable epilepsy. In: Kahane P, Berg A, Loscher W, et al., editors. Drug resistant epilepsies. Montrouge, France: John Libbey Eurotext; 2008. p. 7.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical